Serbian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
International Journal of Cardiology 2016-Mar

Incidence and risk factors for severe renal impairment after first diagnosis of heart failure: A cohort and nested case-control study in UK general practice.

Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Веза се чува у привремену меморију
Alexander Michel
Mar Martín-Pérez
Ana Ruigómez
Luis A García Rodríguez

Кључне речи

Апстрактан

OBJECTIVE

We aimed to evaluate the incidence, time-course and risk factors for severe renal impairment (SRI) among incident heart failure (HF) patients.

RESULTS

Patients aged 1-89years from 2000 to 2005 with incident HF and without SRI or cancer (N=18,049) were identified from The Health Improvement Network (a primary care database representative of the UK population). Patients with a first ever record of SRI during follow-up were identified and eligible non-cases used as controls (N=5377; mean age 74years). Cohort and nested case-control analyses were conducted to identify risk factors for SRI. 2818 patients (15.6%, mean age 75years) in the HF cohort developed SRI over a mean of 2.84years with incidence highest in the first year following HF diagnosis. Hazard ratios (HRs) with 95% confidence intervals (CIs) were as follows: diabetes (1.96, 1.80-2.14), hypertension (1.23, 1.14-1.33), peripheral artery disease (1.29, 1.15-1.45), ischemic cerebrovascular disease (1.14, 1.03-1.26), and anemia (1.19, 1.06-1.34). Several cardiovascular medications were associated with SRI in the case-control analysis, odds ratios (95% CIs): 5.07 (3.87-6.64) for all diuretics, 3.22 (2.83-3.66) for potassium-sparing diuretics, 2.40 (1.96-2.93) for thiazide and related diuretics and 3.27 (2.67-4.01) for loop-diuretics.

CONCLUSIONS

SRI is a frequent complication in patients with newly diagnosed HF. Comorbidities may contribute to its development and should be adequately treated. Robust clinical trial data on beneficial or possibly deleterious effects of diuretics, especially loop-diuretics and potassium-sparing diuretics, on SRI development in HF patients are warranted.

Придружите се нашој
facebook страници

Најкомплетнија база лековитог биља подржана науком

  • Ради на 55 језика
  • Биљни лекови потпомогнути науком
  • Препознавање биљака по слици
  • Интерактивна ГПС мапа - означите биље на локацији (ускоро)
  • Читајте научне публикације повезане са вашом претрагом
  • Претражите лековито биље по њиховим ефектима
  • Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима

Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи.
* Све информације се заснивају на објављеним научним истраживањима

Google Play badgeApp Store badge